CO6321238A2 - Compuesto heterociclico con accion antagonista del glucagon - Google Patents
Compuesto heterociclico con accion antagonista del glucagonInfo
- Publication number
- CO6321238A2 CO6321238A2 CO10122832A CO10122832A CO6321238A2 CO 6321238 A2 CO6321238 A2 CO 6321238A2 CO 10122832 A CO10122832 A CO 10122832A CO 10122832 A CO10122832 A CO 10122832A CO 6321238 A2 CO6321238 A2 CO 6321238A2
- Authority
- CO
- Colombia
- Prior art keywords
- optionally substituted
- ring
- alkyl group
- group
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 102000051325 Glucagon Human genes 0.000 title 1
- 108060003199 Glucagon Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
- 229960004666 glucagon Drugs 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Indole Compounds (AREA)
- Furan Compounds (AREA)
Abstract
Un compuesto caracterizado por la siguiente fórmula: en donde el anillo AA es un anillo benceno opcionalmente sustituido o un heterociclo aromático de 5 ó 6 miembros opcionalmente sustituido;el anillo AB es un heterociclo aromático de 5 miembros opcionalmente sustituido;el anillo AC es un anillo benceno opcionalmente sustituido o un heterociclo aromático de 5 ó 6 miembros opcionalmente sustituido;RA3 es un grupo alquilo C1-6 opcionalmente sustituido, es un grupo cicloalquilo C3-10 opcionalmente sustituido, es un grupo arilo C6-14 opcionalmente sustituido o un grupo heterocíclico opcionalmente sustituido;RA4 es un átomo de hidrógeno o un grupo alquilo C1-6;RA5 es -(CH2)3-COORA11 o -NRA6-CRA7RA8CRA9RA10- COORA11;-RA6, RA7, RA8, RA9, RA11, son cada uno, de modo independiente, un átomo de hidrógeno o un grupo alquilo C1-6;yRA10 es un átomo de hidrógeno, un grupo alquilo C1-6 o un grupo hidroxi,o una de sus sales.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008055250 | 2008-03-05 | ||
JP2009025511 | 2009-02-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6321238A2 true CO6321238A2 (es) | 2011-09-20 |
Family
ID=41056073
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO10122832A CO6321238A2 (es) | 2008-03-05 | 2010-10-04 | Compuesto heterociclico con accion antagonista del glucagon |
Country Status (21)
Country | Link |
---|---|
US (1) | US8436043B2 (es) |
EP (1) | EP2251326A4 (es) |
JP (1) | JP5465658B2 (es) |
KR (1) | KR101616140B1 (es) |
CN (1) | CN102015641B (es) |
AU (1) | AU2009220615B2 (es) |
BR (1) | BRPI0912245A2 (es) |
CA (1) | CA2717138A1 (es) |
CO (1) | CO6321238A2 (es) |
CR (1) | CR11688A (es) |
DO (1) | DOP2010000267A (es) |
EA (1) | EA019752B1 (es) |
EC (1) | ECSP10010526A (es) |
GE (1) | GEP20135844B (es) |
IL (1) | IL207757A (es) |
MA (1) | MA32171B1 (es) |
MX (1) | MX2010009736A (es) |
MY (1) | MY158982A (es) |
NZ (1) | NZ588011A (es) |
WO (1) | WO2009110520A1 (es) |
ZA (1) | ZA201006511B (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
CA2873524C (en) | 2006-05-04 | 2018-02-20 | Boehringer Ingelheim International Gmbh | A polymeric form of 1-((4-methyl-quinazolin-2-yl)methyl)-3-7-(2-butyn-1-yl)-8-(3-(r)-aminopiperidin-1-yl)xanthine |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
EP2210876B1 (en) | 2007-11-01 | 2015-05-20 | Takeda Pharmaceutical Company Limited | Heterocyclic compound as glucagon antagonist |
PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
JP5535931B2 (ja) * | 2008-10-27 | 2014-07-02 | 武田薬品工業株式会社 | 二環性化合物 |
BRPI0923121A2 (pt) | 2008-12-23 | 2015-08-11 | Boehringer Ingelheim Int | Formas salinas de compostos orgânico |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
CA2754904A1 (en) | 2009-03-10 | 2010-09-16 | Takeda Pharmaceutical Company Limited | Benzofuran derivatives |
WO2011027849A1 (ja) * | 2009-09-04 | 2011-03-10 | 武田薬品工業株式会社 | 複素環化合物 |
CN102753161A (zh) | 2009-11-27 | 2012-10-24 | 贝林格尔.英格海姆国际有限公司 | 基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗 |
WO2011083804A1 (ja) * | 2010-01-06 | 2011-07-14 | 武田薬品工業株式会社 | インドール誘導体 |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2011138421A1 (en) | 2010-05-05 | 2011-11-10 | Boehringer Ingelheim International Gmbh | Combination therapy |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
EP3124041A1 (en) | 2010-06-24 | 2017-02-01 | Boehringer Ingelheim International GmbH | Diabetes therapy |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
CA2822017C (en) | 2010-12-23 | 2015-04-07 | Pfizer Inc. | Glucagon receptor modulators |
DK2673260T3 (en) | 2011-02-08 | 2016-10-10 | Pfizer | Glucagonreceptormodulator |
ES2713566T3 (es) | 2011-07-15 | 2019-05-22 | Boehringer Ingelheim Int | Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II |
MX2014000855A (es) | 2011-07-22 | 2014-04-30 | Pfizer | Moduladores receptores de glucagon de quinolinilo. |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
CA2868713A1 (en) | 2012-03-29 | 2013-10-03 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
JP2019517542A (ja) | 2016-06-10 | 2019-06-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | リナグリプチンおよびメトホルミンの組合せ |
KR102021114B1 (ko) | 2017-01-24 | 2019-09-11 | 주식회사 엘지화학 | 페놀의 정제 방법 |
EA039455B1 (ru) * | 2017-01-24 | 2022-01-28 | Алфала Ко., Лтд. | Амидные соединения и их применение |
EP3766879A1 (en) | 2019-07-19 | 2021-01-20 | Basf Se | Pesticidal pyrazole derivatives |
WO2023250316A1 (en) * | 2022-06-22 | 2023-12-28 | Ptc Therapeutics, Inc. | Compounds for treating spinocerebellar ataxia type 3 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4793717A (en) | 1982-05-06 | 1988-12-27 | Minnesota Mining And Manufacturing Company | Device for visually indicating a pressure or temperature condition |
MXPA01008142A (es) | 1999-02-10 | 2003-07-21 | Welfide Corp | Compuestos de amida, y uso medicinal de los mismos. |
IL146006A0 (en) * | 1999-05-17 | 2002-07-25 | Novo Nordisk As | Glucagon antagonists/inverse agonists |
AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
ATE479429T1 (de) | 2000-04-28 | 2010-09-15 | Takeda Pharmaceutical | Antagonisten des melanin-konzentrierenden hormons |
AU2001256733A1 (en) | 2000-05-16 | 2001-11-26 | Takeda Chemical Industries Ltd. | Melanin-concentrating hormone antagonist |
EP1394154A4 (en) | 2001-03-23 | 2005-05-18 | Takeda Pharmaceutical | HETEROCYCLIC DERIVATIVE WITH FIVE MEMBERS OF ALKANOIC ACID |
EP1463715A1 (en) * | 2001-12-03 | 2004-10-06 | Novo Nordisk A/S | Novel glucagon antagonists |
CA2487315A1 (en) | 2002-05-24 | 2003-12-04 | Takeda Pharmaceutical Company Limited | 1,2-azole derivatives with hypoglycemic and hypolipidemic activity |
DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
EP1519723A1 (en) * | 2002-06-27 | 2005-04-06 | Novo Nordisk A/S | Novel glucagon antagonists/inverse agonists |
AR042086A1 (es) | 2002-11-21 | 2005-06-08 | Upjohn Co | N-aril-2- oxazolidinon -5- carboxamidas y sus derivados, usados como agentes antibacterianos |
CA2513102C (en) * | 2003-01-27 | 2011-03-22 | Merck & Co., Inc. | Substituted pyrazoles, compositions containing such compounds and methods of use |
ES2350837T3 (es) | 2003-05-01 | 2011-01-27 | Bristol-Myers Squibb Company | Compuestos de pirazol-amida sustituidos con arilo útiles como inhibidores de quinasas. |
AU2004238240A1 (en) * | 2003-05-09 | 2004-11-25 | Merck & Co., Inc. | Benzimidazoles, compositions containing such compounds and methods of use |
JP4108739B2 (ja) | 2004-06-04 | 2008-06-25 | メルク エンド カムパニー インコーポレーテッド | ピラゾール誘導体、かかる化合物を含む組成物及び使用方法 |
WO2006000020A1 (en) | 2004-06-29 | 2006-01-05 | European Nickel Plc | Improved leaching of base metals |
WO2006017055A2 (en) * | 2004-07-07 | 2006-02-16 | Merck & Co., Inc. | Pyrazole amide derivatives, compositions containing such compounds and methods of use |
JP2008507528A (ja) * | 2004-07-22 | 2008-03-13 | メルク エンド カムパニー インコーポレーテッド | 置換ピラゾール、このような化合物を含有する組成物及び使用方法 |
JP2006112549A (ja) | 2004-10-15 | 2006-04-27 | Jtekt Corp | 自在継手 |
WO2006102067A1 (en) | 2005-03-21 | 2006-09-28 | Merck & Co., Inc. | Substituted aryl and heteroaryl derivatives |
EP2308839B1 (en) | 2005-04-20 | 2017-03-01 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
EP1895898B1 (en) | 2005-06-29 | 2011-02-16 | Compumedics Limited | Sensor assembly with conductive bridge |
JP5577006B2 (ja) | 2005-07-01 | 2014-08-20 | 味の素株式会社 | 迅速スクリーニング方法及び該方法で得られた微生物 |
US7799820B2 (en) | 2005-09-30 | 2010-09-21 | Banyu Pharmaceutical Co., Ltd. | 2-Heterocycle-substituted indole derivatives for treating diabetes and associated conditions |
US7696248B2 (en) * | 2005-11-17 | 2010-04-13 | Eli Lilly And Company | Glucagon receptor antagonists, preparation and therapeutic uses |
WO2007089031A1 (en) | 2006-02-01 | 2007-08-09 | Takeda Pharmaceutical Company Limited | Piperidine derivatives as tachykinin receptor antagonists |
TW200821284A (en) | 2006-10-03 | 2008-05-16 | Merck & Co Inc | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
EP2210876B1 (en) | 2007-11-01 | 2015-05-20 | Takeda Pharmaceutical Company Limited | Heterocyclic compound as glucagon antagonist |
WO2010000020A1 (en) | 2008-06-30 | 2010-01-07 | Cathrx Ltd | A catheter |
-
2009
- 2009-03-04 CN CN200980116371.3A patent/CN102015641B/zh not_active Expired - Fee Related
- 2009-03-04 EP EP09717906A patent/EP2251326A4/en not_active Withdrawn
- 2009-03-04 CA CA2717138A patent/CA2717138A1/en not_active Abandoned
- 2009-03-04 NZ NZ588011A patent/NZ588011A/en not_active IP Right Cessation
- 2009-03-04 GE GEAP2009011962 patent/GEP20135844B/en unknown
- 2009-03-04 AU AU2009220615A patent/AU2009220615B2/en not_active Ceased
- 2009-03-04 KR KR1020107022118A patent/KR101616140B1/ko not_active IP Right Cessation
- 2009-03-04 MY MYPI2010004008A patent/MY158982A/en unknown
- 2009-03-04 MX MX2010009736A patent/MX2010009736A/es active IP Right Grant
- 2009-03-04 BR BRPI0912245A patent/BRPI0912245A2/pt not_active IP Right Cessation
- 2009-03-04 JP JP2010501939A patent/JP5465658B2/ja not_active Expired - Fee Related
- 2009-03-04 WO PCT/JP2009/054095 patent/WO2009110520A1/ja active Application Filing
- 2009-03-04 US US12/920,973 patent/US8436043B2/en not_active Expired - Fee Related
- 2009-03-04 EA EA201071032A patent/EA019752B1/ru not_active IP Right Cessation
-
2010
- 2010-08-23 IL IL207757A patent/IL207757A/en not_active IP Right Cessation
- 2010-09-03 DO DO2010000267A patent/DOP2010000267A/es unknown
- 2010-09-10 ZA ZA2010/06511A patent/ZA201006511B/en unknown
- 2010-09-23 CR CR11688A patent/CR11688A/es unknown
- 2010-09-29 MA MA33207A patent/MA32171B1/fr unknown
- 2010-10-04 CO CO10122832A patent/CO6321238A2/es active IP Right Grant
- 2010-10-05 EC EC2010010526A patent/ECSP10010526A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN102015641A (zh) | 2011-04-13 |
CR11688A (es) | 2010-12-08 |
MY158982A (en) | 2016-11-30 |
KR101616140B1 (ko) | 2016-04-27 |
US8436043B2 (en) | 2013-05-07 |
EA019752B1 (ru) | 2014-06-30 |
ZA201006511B (en) | 2011-11-30 |
AU2009220615A2 (en) | 2010-11-11 |
US20120270865A2 (en) | 2012-10-25 |
JP5465658B2 (ja) | 2014-04-09 |
MX2010009736A (es) | 2010-09-30 |
DOP2010000267A (es) | 2010-09-30 |
WO2009110520A1 (ja) | 2009-09-11 |
IL207757A0 (en) | 2010-12-30 |
ECSP10010526A (es) | 2010-11-30 |
CA2717138A1 (en) | 2009-09-11 |
CN102015641B (zh) | 2014-01-01 |
IL207757A (en) | 2015-07-30 |
AU2009220615A1 (en) | 2009-09-11 |
EP2251326A1 (en) | 2010-11-17 |
BRPI0912245A2 (pt) | 2019-09-24 |
EA201071032A1 (ru) | 2011-06-30 |
EP2251326A4 (en) | 2011-08-31 |
AU2009220615B2 (en) | 2013-12-19 |
NZ588011A (en) | 2012-06-29 |
GEP20135844B (en) | 2013-06-10 |
US20120053173A1 (en) | 2012-03-01 |
KR20100126470A (ko) | 2010-12-01 |
JPWO2009110520A1 (ja) | 2011-07-14 |
MA32171B1 (fr) | 2011-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6321238A2 (es) | Compuesto heterociclico con accion antagonista del glucagon | |
CU20140105A7 (es) | Composición para el control de plagas que incluye un derivado de iminopiridina novedoso | |
CR20160007A (es) | Nuevos compuestos triciclicos | |
AR098316A1 (es) | Derivados pirazolicos condensados, composiciones y métodos para modular los receptores x farnesoides | |
AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
PE20180455A1 (es) | Compuestos heterociclicos como inhibidores de lsd1 | |
ECSP11010912A (es) | Compuestos de pirrol | |
AR083003A1 (es) | Lactamas sustituidas por piperidinilo como moduladores de gpr119 | |
AR078463A1 (es) | Composicion y metodo para controlar plagas de artropodos | |
UY33403A (es) | Compuestos orgánicos con novedosas isoxazolinas, sus n-óxidos, s-óxidos y sales | |
AR076754A1 (es) | Dihidropirimidinas y proceso de obtencion de las mismas | |
AR081369A1 (es) | Compuestos de 2-5-6-7-tetrahidro-(1,4) oxazepin-3-ilamina o 2,3,6,7-tetrahidro-(1,4) oxazepin-5-ilamina, sus procesos de obtencion y composiciones farmaceuticas que los contienen | |
PE20181487A1 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj) | |
PE20131143A1 (es) | Nuevas aminopirazoloquinazolinas | |
CR20130500A (es) | Moduladores de los receptores de hormonas nucleares | |
AR090859A1 (es) | Inhibidores ciclicos del enlace eter de dgat1 | |
RS54488B1 (en) | NALOXOL-POLYETHYLENE GLYCOL CRYSTAL CONJUGATE | |
AR109635A1 (es) | Mezcla aditiva | |
AR087494A1 (es) | Derivados de isoxazolina como compuestos insecticidas | |
AR090086A1 (es) | COMPUESTO DE 1H-INDAZOL-3-CARBOXAMIDA COMO INHIBIDORES DE LA GLUCOGENO SINTASA CINASA 3 b | |
CY1116388T1 (el) | 5-(φαινυλο/πυριδινυλο-αιθινυλο)-2-πυριδινο/2-πυριμιδινο-καρβοξαμιδια ως mglur5 ρυθμιστες | |
ECSP13012495A (es) | Compuestos de tetrahidrofuranilo disustituidos como antagonistas del receptor b1 de bradiquinina | |
CR20160562A (es) | Péptidos como agonistas de la oxitocina | |
CO5700777A2 (es) | Derivados de 4-(2-fenilsulfanil-fenil)-1,2,3,6-tetrahidropiridina como inhibidores de la recaptacion de serotonina | |
AR074818A1 (es) | Dihidropiridona-amidas como moduladores de p2x7 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted |